logo-loader
viewPropanc Biopharma, Inc.

Propanc Biopharma plans to advance clinical trials on lead cancer drug PRP

The company said it has completed the preclinical development of PRP

Cancer cell
Cancer stem cells have the ability to remain dormant, the company said, which makes them radio- and chemo-resistant while remaining metastatic 

Propanc Biopharma Inc (OTCMKTS:PPCB) said it is making significant progress with its lead product, cancer-fighting drug PRP, as a targeted cancer stem cell therapy. 

In a statement, the company said it has completed the preclinical development of PRP and it plans to advance clinical trials in the near future. 

PRP, a formulation of two pancreatic proenzymes, works by suppressing cellular pathways involved in the Epithelial to Mesenchymal Transition, a process which causes metastasis in cancer stem cells (CSCs) and ultimately can result in secondary tumors. 

“Our findings from our recently published paper confirms the mechanism of action of PRP, which may prove to be [an] effective tool in the fight against metastatic cancer, the main cause of patient death for sufferers,” Chief Scientific Officer Julian Kenyon said in a statement.

“By targeting CSCs, PRP is targeting the fundamental mechanism by which cancer spreads, especially after exposure to chemo or radiation, because they are non-dividing cells and are therefore resistant to standard treatments.”

READ: Propanc Biopharma publishes promising study of its metastatic cancer drug in peer-reviewed medical journal

CSCs have the ability to remain dormant, the company said, which makes them radio- and chemo-resistant while remaining metastatic. 

“We continue to make significant progress with our scientific understanding and development of our lead product, PRP, as a targeted cancer stem cell therapy,” CEO James Nathanielsz said.

“The global metastatic cancer treatment market is predicted to reach nearly $100 Billion over the next 5-year period, and we believe PRP has the potential to impact the way we view and treat cancer, by minimizing the potential for its return and spread in patients.”

The recently published scientific paper, entitled “Pancreatic Proenzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumor engrafting,” was published on August 6 in the journal Scientific Reports. 

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Propanc Biopharma, Inc.

Price: 0.24647 USD

OTCQB:PPCB
Market: OTCQB
Market Cap: $323.25 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medicenna Therapeutics completes Phase 2B study on cancer drug mdna55

Medicenna Therapeutics (TSE: MDNA) CFO Elizabeth Williams joined Steve Darling from Proactive Vancouver at LD MIcrocap Conference in Vancouver with news about their lead drug mdma55. Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization...

4 hours, 8 minutes ago

2 min read